Study results from a promising dry eye disease candidate and a blog about corneal cross-linking are two of the best-performing cornea/external disease items from September.
Read the top pieces of Healio/OSN coverage below.
Dry eye candidate demonstrates promising results in phase 2b study
AR-15512 achieved statistical significance for multiple sign and symptom endpoints in patients with dry eye disease, according to a press release from Aerie Pharmaceuticals. Read more.
NCX 4251 fails to meet primary, secondary endpoints in phase 2b blepharitis trial
NCX 4251 did not meet the primary or secondary